Richard A. Larson

Q: What Schools Are Affiliated With Richard A. Larson

Richard A. Larson is affiliated with the following schools: University of California, Berkeley, MD Anderson Cancer Center, Ohio State University, Dartmouth College, University of Chicago, Case Western Reserve University, University of Bologna, Karolinska Institute, Duke University, University of Münster

Richard A. Larson's AcademicInfluence.com Rankings

Richard A. Larson

Mathematics

#4609

World Rank

#6528

Historical Rank

Operations Research

#21

World Rank

#21

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Why Is Richard A. Larson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard A. Larson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) (3476)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) (3337)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. (2003) (2541)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) (1736)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. (2002) (1726)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). (2002) (1610)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) (1382)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) (1300)
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) (1255)
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. (2010) (1224)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) (1196)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. (2000) (1074)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. (2015) (951)
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. (2017) (929)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. (2001) (861)
Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) (754)
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (720)
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. (1986) (681)
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. (2001) (678)
International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (2009) (659)
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. (2003) (650)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) (623)
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. (1995) (613)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. (2008) (599)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). (2003) (598)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (2016) (595)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (2019) (585)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL (2018) (575)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. (2006) (539)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. (2013) (536)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2010) (516)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. (2006) (508)
Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. (1983) (489)
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. (2008) (487)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. (2011) (475)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). (2010) (463)
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations (2008) (458)
MicroRNA expression in cytogenetically normal acute myeloid leukemia. (2008) (454)
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. (2005) (449)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (2012) (432)
Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. (1984) (423)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence (2005) (422)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2009) (422)
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. (2002) (403)
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. (2012) (386)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. (2007) (376)
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. (2002) (372)
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia (2007) (371)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. (2007) (366)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. (2011) (364)
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. (2008) (363)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib (2008) (363)
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. (2007) (359)
Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study (2017) (355)
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. (2010) (349)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. (2005) (335)
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. (2010) (333)
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. (2008) (326)
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. (2011) (324)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. (2006) (317)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. (2007) (314)
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. (1999) (309)
Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. (1993) (306)
Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. (1999) (302)
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). (1992) (296)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. (2008) (288)
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. (2008) (287)
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. (2014) (282)
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. (2011) (270)
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. (2008) (266)
Therapy-related myeloid leukemia. (1996) (261)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. (2006) (260)
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. (1993) (253)
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. (1998) (252)
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. (1996) (251)
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. (2003) (250)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. (2005) (249)
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. (2012) (247)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. (2007) (244)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. (2014) (239)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. (2019) (239)
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. (1987) (236)
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II (1993) (235)
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. (2006) (233)
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) (2002) (220)
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (220)
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. (2022) (218)
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. (1986) (214)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study (2013) (211)
Therapy-related myeloid leukemia. (2008) (211)
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. (2003) (210)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. (2007) (207)
Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. (1986) (203)
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. (2004) (202)
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes (1986) (198)
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). (2001) (194)
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (191)
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. (2008) (190)
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. (2012) (190)
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients (2014) (188)
Morphology in Ki‐1 (CD30)‐Positive Non Hodgkin's Lymphoma Is Correlated with Clinical Features and the Presence of a Unique Chromosomal Abnormality, t(2;5)(p23;q35) (1990) (188)
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia (1990) (187)
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. (2002) (178)
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. (2005) (176)
The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. (1989) (176)
Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. (1992) (173)
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (2010) (169)
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. (2012) (168)
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. (2004) (166)
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia (2004) (165)
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. (2012) (163)
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. (2009) (162)
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. (2012) (161)
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. (1997) (161)
Associations between morphology, karyotype, and clinical features in myeloid leukemias. (1987) (158)
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. (2011) (156)
Deletions of interferon genes in acute lymphoblastic leukemia. (1990) (152)
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. (2001) (147)
Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). (1989) (143)
Assignment of CSF-1 to 5q33.1: evidence for clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders. (1987) (142)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. (2005) (142)
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. (2013) (141)
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop † (2002) (141)
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. (1999) (140)
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. (2005) (139)
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. (2008) (139)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. (2005) (137)
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. (2006) (136)
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. (1993) (135)
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. (2005) (134)
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia (2002) (133)
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. (2009) (133)
Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805 (2005) (132)
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. (2011) (131)
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia (2016) (123)
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. (2001) (122)
Studies of the human c-myb gene and its product in human acute leukemias. (1986) (121)
Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. (1995) (120)
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (2006) (120)
Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. (1988) (118)
Therapy-related myeloid neoplasms (2009) (117)
miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia (2012) (117)
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia (2016) (116)
t(3;21)(q26;q22): A Recurring Chromosomal Abnormality in Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia (1990) (116)
Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11) (1990) (116)
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. (2011) (114)
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (2008) (114)
Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. (2010) (113)
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (113)
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. (2012) (112)
Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) (2006) (111)
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (111)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) * (2010) (111)
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. (2010) (111)
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia (2002) (110)
MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia. (2007) (109)
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (2013) (109)
Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. (1992) (108)
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). (1983) (108)
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. (2004) (108)
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. (2007) (107)
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. (2018) (106)
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. (2000) (106)
Gemtuzumab ozogamicin: time to resurrect? (2012) (106)
Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403 (2014) (105)
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. (2004) (105)
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial (2013) (105)
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy (2010) (104)
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. (2013) (103)
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. (2004) (102)
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). (2001) (101)
Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. (1996) (101)
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies (2006) (100)
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. (2005) (99)
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia–rearranged leukemia (2013) (99)
Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β‐Catenin Signaling (2012) (98)
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (2009) (97)
Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? (2007) (96)
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (2021) (96)
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. (2007) (93)
CBFA2(AML1) Translocations With Novel Partner Chromosomes in Myeloid Leukemias: Association With Prior Therapy (1998) (92)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (2012) (92)
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma (2004) (92)
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) (2014) (90)
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase (2012) (90)
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. (2013) (90)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. (2006) (89)
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (88)
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. (2008) (88)
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. (2009) (88)
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (88)
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study (2010) (87)
Etiology and management of therapy-related myeloid leukemia. (2007) (87)
End points to establish the efficacy of new agents in the treatment of acute leukemia. (2007) (87)
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. (2010) (85)
Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. (1987) (85)
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. (2019) (84)
Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion (1993) (84)
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016) (83)
Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002 (2003) (83)
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. (1992) (82)
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. (2010) (82)
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. (1988) (82)
Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. (2017) (82)
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase (2012) (81)
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia (1998) (81)
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. (2006) (81)
High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study. (1987) (79)
Additional cytogenetic abnormalities in adults with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B (2004) (76)
Treatment of adult acute lymphoblastic leukemia. (1997) (76)
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation (2007) (75)
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002 (2014) (74)
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. (2013) (73)
Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation (2001) (73)
Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. (1988) (73)
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (2008) (73)
Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. (1989) (72)
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. (2010) (71)
Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models (2016) (70)
The evolving challenge of therapy-related myeloid neoplasms. (2013) (69)
Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies (2016) (69)
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia (2014) (69)
Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia (2008) (67)
Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow transplantation. (1991) (67)
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. (2014) (66)
Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). (2009) (66)
Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders. (1992) (65)
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. (2011) (65)
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. (2012) (65)
Simvastatin Radiosensitizes Differentiated and Stem‐Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation (2014) (65)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. (2005) (64)
Acute lymphoblastic leukaemia: diagnosis and classification. (2002) (64)
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. (1996) (64)
Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. (2005) (63)
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. (2003) (62)
Low‐dose cytosine arabinoside (Ara‐C) therapy in the myelodysplastic syndromes and acute leukemia (1985) (61)
Management of acute lymphoblastic leukemia in older patients. (2006) (61)
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype (2014) (60)
Overexpression and knockout of miR-126 both promote leukemogenesis. (2015) (60)
A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). (1984) (60)
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old (2007) (60)
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) (2013) (59)
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide (2012) (59)
IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. (2007) (59)
Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. (1996) (59)
miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. (2016) (59)
RAS, FLT3, and TP53 mutations in therapy‐related myeloid malignancies with abnormalities of chromosomes 5 and 7 (2004) (58)
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence (2009) (58)
Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma (1997) (58)
dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations of TP53 (1997) (58)
Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. (1993) (57)
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. (2002) (57)
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti‐B4‐blocked ricin or high‐dose cytarabine (2003) (57)
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. (1986) (57)
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study (2002) (56)
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) (2016) (56)
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study (2019) (56)
The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment (2014) (56)
Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL). (2009) (55)
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome (2009) (55)
Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model (2015) (55)
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia (2014) (55)
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. (2021) (55)
Metastatic adenocarcinoma arising in a congenital foregut cyst of the esophagus: a case report with review of the literature. (1998) (54)
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. (2002) (54)
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. (2017) (53)
Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes. (2009) (53)
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. (2015) (53)
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. (2019) (53)
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes (2005) (53)
High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial (2009) (53)
A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. (1992) (52)
Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside (1984) (52)
Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study. (1989) (51)
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. (2000) (51)
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia (2017) (50)
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study (2019) (50)
Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism* (2010) (50)
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd (2014) (50)
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. (2011) (50)
A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer (1999) (50)
Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy (1982) (49)
ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) (2010) (49)
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. (2015) (49)
ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes (2013) (49)
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211 (2003) (49)
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia (2018) (49)
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia (2008) (49)
SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) (2016) (48)
Managing CNS disease in adults with acute lymphoblastic leukemia (2018) (48)
Is there a best TKI for chronic phase CML? (2015) (48)
The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. (1995) (48)
Establishment and characterization of a megakaryoblast cell line with amplification of MLL (1998) (48)
Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment. (2007) (47)
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. (2012) (47)
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning (2006) (47)
Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a (2015) (47)
Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. (2008) (45)
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group (2012) (45)
Assignment of the GM-CSF, CSF-1, and FMS genes to human chromosome 5 provides evidence for linkage of a family of genes regulating hematopoiesis and for their involvement in the deletion (5q) in myeloid disorders. (1986) (45)
High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study (1986) (45)
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism (2016) (44)
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (44)
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. (2004) (43)
A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. (1987) (42)
Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (2016) (42)
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 (2016) (42)
CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. (1998) (42)
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia. (1988) (42)
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials (2016) (42)
Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib (2008) (42)
Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2012) (42)
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. (2006) (42)
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. (2011) (41)
Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). (2015) (41)
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. (2019) (41)
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily (2014) (41)
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia (2013) (41)
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. (2013) (41)
Trisomy 21 as the sole acquired chromosomal abnormality in children with acute lymphoblastic leukemia. (1992) (41)
High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. (1998) (41)
Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients) (2012) (40)
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. (1990) (40)
Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) (2014) (40)
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. (2016) (40)
Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. (2000) (39)
Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial (2009) (39)
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials (2013) (39)
Treatment of Acute Promyelocytic Leukemia in Adults. (2018) (39)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. (2012) (39)
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy (2017) (38)
Myeloid leukemia after hematotoxins. (1996) (38)
Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib. (2007) (37)
Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301. (2006) (37)
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. (2010) (37)
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU (2015) (37)
Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. (1992) (36)
Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia [letter] (1991) (36)
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL1 (2003) (36)
Acute lymphoblastic leukemia: older patients and newer drugs. (2005) (36)
Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients. (1991) (36)
Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. (2005) (36)
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy (2014) (36)
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. (2000) (35)
Next generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma (2015) (35)
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011) (2013) (35)
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101. (2007) (35)
Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) (2010) (35)
Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial. (2010) (34)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial (2021) (34)
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. (2004) (34)
Psychosocial symptomatology, personal growth, and development among young adult patients following the diagnosis of leukemia or lymphoma. (1988) (34)
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification (2014) (34)
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. (2020) (34)
Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis (2008) (34)
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). (2020) (34)
Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib. (2007) (34)
Auto-SCT for AML in second remission: CALGB Study 9620 (2009) (34)
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. (2017) (33)
Acute leukemia in adults: Recent developments in diagnosis and treatment (1994) (33)
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia (2016) (33)
Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study. (2006) (33)
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. (2020) (32)
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia. (2014) (32)
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. (1996) (32)
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. (2012) (32)
High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. (2015) (32)
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). (2014) (32)
Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study (2015) (32)
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. (2015) (32)
Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. (2012) (32)
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. (2010) (32)
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804 (2009) (32)
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23) (2004) (31)
Time to Complete Cytogenetic Response (CCyR) Does Not Affect Long-Term Outcomes for Patients on Imatinib Therapy. (2007) (31)
Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: Three cases and review of the literature (1988) (31)
Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study (2013) (30)
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. (2015) (30)
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. (2011) (30)
A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial (2010) (30)
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease (2010) (30)
Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia (2004) (29)
Fto Plays an Oncogenic Role in Acute Myeloid Leukemia As a N6-Methyladenosine RNA Demethylase (2016) (29)
Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015). (2007) (29)
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. (2007) (29)
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival (2016) (29)
The spectrum of somatic mutations in high‐risk acute myeloid leukaemia with ‐7/del(7q) (2014) (28)
Prognosis and Therapy When Acute Promyelocytic Leukemia and Other “Good Risk” Acute Myeloid Leukemias Occur as a Therapy-Related Myeloid Neoplasm (2011) (28)
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study (2005) (28)
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. (2018) (28)
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). (2018) (28)
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 (2011) (28)
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. (2006) (28)
Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study (2009) (28)
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results (2021) (28)
c-myc and c-myb expression in acute myelogenous leukemia. (1992) (28)
A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies (2000) (28)
Nilotinib ( formerly AMN 107 ) , a highly selective BCR-ABL tyrosine kinase inhibitor , is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia (2008) (27)
Familial myeloid leukemia associated with loss of the long arm of chromosome 5. (1996) (27)
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 (2012) (27)
Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study (1989) (27)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. (1993) (27)
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. (2009) (26)
Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808 (2013) (26)
Long‐term follow‐up of cancer and leukemia group B studies in acute myeloid leukemia (1997) (26)
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901 (2009) (26)
Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study (1993) (26)
Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients. (1992) (26)
Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. (1992) (26)
Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study. (2005) (26)
Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. (2007) (26)
Immune reconstitution after combined haploidentical and umbilical cord blood transplant (2013) (25)
Reimmunization after allogeneic bone marrow transplantation. (1995) (25)
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance (2013) (25)
A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. (2005) (25)
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis (2019) (25)
Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature. (1995) (25)
Current use and future development of gemtuzumab ozogamicin. (2001) (25)
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? (2011) (25)
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial (2022) (25)
Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL (2010) (24)
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia (2012) (24)
Clinical outcomes of IDH2‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib (2020) (24)
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. (2019) (24)
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study (2011) (24)
Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd (2012) (24)
CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. (2011) (24)
High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. (1998) (23)
Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia. (1994) (23)
Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (mylotarg™, cma-676) (2000) (23)
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. (2014) (23)
Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia (2005) (23)
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. (2004) (23)
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 (2018) (22)
Therapy-Related Myelodysplastic Syndrome and Myeloid Leukemia (2008) (22)
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia (2012) (22)
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML) (2012) (22)
A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL). (2006) (22)
Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive (1998) (22)
Abstract CT184: Gilteritinib significantly prolongs overall survival in patients withFLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial (2019) (22)
Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. (1995) (21)
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (21)
Management of myelodysplastic syndromes. (1985) (21)
The strategic role of laparotomy in staging Hodgkin's disease. (1982) (21)
Mevalonic acid induces DNA synthesis in chronic lymphocytic leukemia cells. (1984) (21)
Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 (2010) (21)
MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. (2016) (21)
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. (1996) (21)
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure (1991) (21)
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia (2017) (21)
Therapy for acute myeloid leukemia and acute lymphoblastic leukemia in adults (1991) (20)
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. (2011) (20)
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia (2016) (20)
Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). (2005) (20)
ACUTE MYELOID LEUKAEMIA FOLLOWING INTERFERON‐ALFA TREATMENT OF HAIRY CELL LEUKAEMIA (1993) (20)
Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia (1991) (20)
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (20)
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes (2013) (20)
Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up (2011) (20)
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance) (2013) (19)
HYPERSENSITIVITY REACTION TO HIGH‐DOSE CYTARABINE (1989) (19)
Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901). (2007) (19)
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia. (2010) (19)
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. (1994) (19)
Progress and challenges in the therapy of adult acute lymphoblastic leukemia (2003) (19)
AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results (2021) (19)
Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study (2008) (19)
Rates of cholesterol biosynthesis are related to early differentiation in acute non‐lymphocytic leukaemia cells (1983) (18)
Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer (2021) (18)
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. (2003) (18)
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. (2016) (18)
Heterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma. (1989) (18)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. (2012) (18)
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). (2012) (18)
Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia. (1991) (18)
A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) (2007) (18)
The U.S. trials in adult acute lymphoblastic leukemia. (2004) (17)
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (2004) (17)
Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy. (1982) (17)
Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2015) (17)
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. (1992) (17)
Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd (2010) (17)
Corrigendum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (Leukemia (2016) 30 (1672-1681) DOI: 10.1038/leu.2016.69) (2016) (17)
Brincidofovir treatment of acyclovir‐resistant disseminated varicella zoster virus infection in an immunocompromised host (2016) (17)
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. (2017) (17)
Acute Lymphocytic Leukemia in Adults (2000) (17)
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. (2019) (17)
Neutrophils are required for the DNA synthetic response of human lymphocytes to mevalonic acid: evidence suggesting that a nonsterol product of mevalonate is involved. (1982) (17)
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103) (2014) (17)
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). (2018) (17)
Der(5)t(5;7)(q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders. (1989) (16)
Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data. (2006) (16)
Analysis of 830 patients with rectal adenocarcinoma. (1969) (16)
Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance. (2007) (16)
Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. (2006) (16)
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant (2010) (16)
Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer (2018) (16)
The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study (1992) (16)
Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. (1994) (16)
Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia [letter] (1991) (16)
Genetic Pathways Leading to Therapy-Related Myeloid Neoplasms (2011) (16)
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study (2012) (15)
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. (2014) (15)
Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study (2007) (15)
Fifty Years of Clinical Research by the Leukemia Committee of the Cancer and Leukemia Group B (2006) (15)
Detection of Canonical Hedgehog Signaling in Breast Cancer by 131-Iodine-Labeled Derivatives of the Sonic Hedgehog Protein (2012) (15)
Preliminary Experience with a New Chemotherapy Regimen for Adults with Acute Lymphoblastic Leukemia (2001) (15)
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. (2022) (15)
Listeriosis after 2-chlorodeoxyadenosine treatment. (1993) (15)
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication (2021) (15)
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia (2016) (15)
Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. (2016) (15)
Response to 5‐azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings (1982) (15)
A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) (2007) (15)
t(1;3)(p36;p21) is a recurring therapy‐related translocation (2002) (14)
Dasatinib (SPRYCEL®) in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results from the CA180-015 ‘START-L’ Study. (2006) (14)
Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms (2008) (14)
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. (1989) (14)
Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712. (2009) (14)
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer (2020) (14)
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. (2021) (14)
Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review (2005) (14)
Imatinib is still recommended for frontline therapy for CML. (2018) (14)
Polymorphisms in the MLL breakpoint cluster region (BCR) (2003) (14)
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. (1991) (14)
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia (2018) (14)
Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432). (2007) (14)
Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035 (2008) (14)
Influence of related donor age on outcomes after peripheral blood stem cell transplantation. (2012) (14)
Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation: Toxicities with maintenance nivolumab after allogeneic stem cell transplantation. (2020) (14)
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia (2018) (14)
Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013 (2003) (14)
Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? (2003) (14)
Myelodysplasia: when to treat and how. (2006) (14)
Acral lividosis--a sign of myeloproliferative diseases. Hyperleukocytosis syndrome in chronic myelogenous leukemia. (1987) (13)
Dose-intensive therapy for adult acute lymphoblastic leukemia. (1999) (13)
Treatment of Biologically Determined Subsets of Acute Lymphoblastic Leukemia in Adults: Cancer and Leukemia Group B Studies (1997) (13)
Successful allogeneic transplantation of patients with suspected prior invasive mold infection (2007) (13)
Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study (2017) (13)
Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710 (2011) (13)
Analysis of 860 patients with carcinoma of the transverse and descending colon. (1970) (13)
Pepsi® or Coke®? Influence of acid on dasatinib absorption (2018) (13)
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance) (2018) (12)
Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (2010) (12)
Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS) (2009) (12)
Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. (2009) (12)
Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide. (2009) (12)
G3139, a BCL-2 antisense oligo-nucleotide, in AML. (2004) (12)
A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701 (2018) (12)
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products (2008) (12)
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). (2006) (12)
Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study (2008) (12)
Cytochalasin B is a potent mitogen for chronic lymphocytic leukemia cells in vitro. (1983) (12)
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia (2009) (12)
Current practices in the management of chronic myeloid leukemia. (2013) (12)
Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study, (2011) (12)
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant (2019) (12)
Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age. (2005) (12)
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). (2006) (12)
High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710) (2008) (12)
Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902 (2015) (11)
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia (1993) (11)
Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia (1993) (11)
Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. (2010) (11)
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) (2012) (11)
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. (2021) (11)
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107 (2008) (11)
Induction of T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo (2003) (11)
Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study. (2005) (11)
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2021) (11)
Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd, (2011) (11)
Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study (2015) (11)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy (2021) (11)
Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML). (2010) (11)
Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. (2006) (11)
Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS). (2005) (11)
Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (10)
Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. (2017) (10)
The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML). (2004) (10)
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). (2014) (10)
An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. (2017) (10)
Analysis of 830 cases of rectal adenocarcinoma. 1. Progressively improved results of treatment. (1969) (10)
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia (2021) (10)
Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2020) (10)
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia (2015) (10)
Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. (2012) (10)
Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data. (2009) (10)
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002 (2003) (9)
Canine cell line, IPC‐366, as a good model for the study of inflammatory breast cancer (2017) (9)
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). (2019) (9)
Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection. (2016) (9)
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). (2021) (9)
Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). (2007) (9)
'Golden tongue' syndrome caused by Ramichloridium schulzeri. (1985) (9)
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia (2008) (9)
Allogeneic hematopoietic cell transplantation for adults with ALL (2008) (9)
Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine. (2005) (9)
Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio. (2019) (9)
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. (1996) (9)
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997 (2015) (9)
Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engrafment and durable remissions. (2011) (9)
Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML). (2009) (9)
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. (1992) (9)
Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study (2010) (8)
Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study. (2009) (8)
An analysis of patients with carcinoma of the right colon. (1968) (8)
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy (2021) (8)
The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis. (2007) (8)
Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials (2017) (8)
Erratum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (8)
Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP). (2005) (8)
Pre-Donor Evaluation of an HLA Matched Sibling Identifies a Novel Inherited RUNX1 Mutation Encoding a Missense Mutation Found Outside of the RUNT Domain in Familial Platelet Disorder (2010) (8)
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival (2020) (8)
Results from the U.S. Life after Stopping TKIs (LAST) Study (2017) (8)
Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia (1990) (8)
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) (2015) (8)
What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity? (2014) (8)
Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461 (2004) (8)
Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study (2011) (8)
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. (2020) (8)
Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99. (2004) (7)
Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes. (2009) (7)
Patched Targeting Peptides for Imaging and Treatment of Hedgehog Positive Breast Tumors (2014) (7)
Outcome of Adolescents and Young Adults (AYAs) with Non-M3 Acute Myeloid Leukemia (AML) Treated on Children's Oncology Group (COG) Trials Compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) Trials (2010) (7)
Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors. (2021) (7)
FLT 3 Mutation Status is a Predictor of Early Death in Pediatric Acute Promyelocytic Leukemia : A Report From The Children ' s Oncology Group (7)
Acute Lymphoblastic Leukemia: Clinical Presentation, Diagnosis, and Classification (2020) (7)
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. (2004) (7)
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd. (2013) (7)
A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy. (2017) (7)
Chromosome changes in hematologic malignancies (1981) (7)
A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia. (2016) (7)
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). (2014) (7)
Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50 (2014) (7)
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). (2000) (7)
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan (2009) (7)
Nelarabine in the treatment of refractory T-cell malignant diseases (2006) (7)
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications (2022) (7)
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101 (2013) (7)
Activating RAS mutations in therapy-related myeloid disorders associated with deletions of chromosomes 5 and 7. (1996) (7)
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. (2020) (7)
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment (2016) (7)
MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). (2009) (6)
The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML. (2006) (6)
study in chronic-phase chronic myeloid leukemia : a subanalysis of the IRIS Imatinib pharmacokinetics and its correlation with response and safety (2008) (6)
Features of Frailty Are Surprisingly Common in Adults 50 Years and Older Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in the Modern Era (2011) (6)
Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia (2009) (6)
Hypercalcemia and lytic bone lesions in a patient with B-cell non-Hodgkin's lymphoma. (1984) (6)
Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML). (2012) (6)
The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up. (2011) (6)
Cholesterol and mevalonic acid are independent requirements for the in vitro proliferation of human bone marrow granulocyte progenitor cells: studies using ML-236B (1983) (6)
A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902. (2004) (6)
Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. (2004) (6)
Outcomes by Cytogenetic and Molecular Response at 12 and 18 Months of Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the IRIS Trial. (2006) (6)
Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up. (2020) (6)
Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results. (2005) (6)
Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) (2014) (6)
Cell-cycle characteristics - alterable determinants of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid-leukemia. (1993) (6)
Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model. (2005) (6)
Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST). (2004) (6)
A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance) (2016) (6)
Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies (2011) (6)
Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts) (2011) (6)
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) (2018) (6)
The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes. (1994) (5)
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202 (2021) (5)
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study. (2009) (5)
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. (1993) (5)
CML: live long and prosper. (2011) (5)
Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Study C9710. (2010) (5)
Therapy-related myeloid sarcoma with an NPM1 mutation (2010) (5)
Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) (2012) (5)
Amelanocytic anhidrotic alopecia areata-like phenotype after allogeneic hematopoietic cell transplant. (2012) (5)
Complex rearrangement of the T cell receptor in large granular lymphocytosis associated with myeloid suppression. (1990) (5)
Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study (2007) (5)
Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study (2014) (5)
Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors. (2009) (5)
Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia. (1991) (5)
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. (2009) (5)
Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001) (2013) (5)
Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001. (2007) (5)
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. (2004) (5)
Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102). (2007) (5)
Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia. (2006) (5)
Trees, bialgebras and intrinsic numerical algorithms (1990) (4)
miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53 (2014) (4)
Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105. (2006) (4)
Abstract PD03-06: Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with post-mastectomy radiation (2012) (4)
Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997 (2010) (4)
Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody (1991) (4)
Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies. (2015) (4)
Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. (2010) (4)
MYELOID LEUKEMIA AFTER CYTOTOXIC THERAPY AND OTHER HEMATOTOXINS (2000) (4)
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to t (2019) (4)
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases (2004) (4)
Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy. (2009) (4)
R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission (2012) (4)
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML (2022) (4)
Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study. (2007) (4)
Pre-Treatment Cytogenetics Predict Complete Remission and Long-Term Outcome in Patients (Pts) ≥60 Years with Acute Myeloid Leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. (2004) (4)
Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy. (2004) (4)
Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. (2009) (4)
Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides (2015) (4)
Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantation--A case-cohort analysis. (2014) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL (2021) (4)
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? (2019) (4)
NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). (2016) (4)
Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd (2019) (4)
PML-RARα isoform at diagnosis is associated with disease-free survival (DFS) in patients enrolled in the intergroup trial (C-9710) for treatment of acute promyelocytic leukemia (APL). (2006) (4)
FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) (2018) (4)
Differential Effect of Phosphorylation-Defective Survivin on Radiation Response in Estrogen Receptor-Positive and -Negative Breast Cancer (2015) (4)
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. (2020) (4)
Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Unexpected Renal Toxicity (2009) (4)
Current management of acute lymphoblastic leukemia in adults. (1995) (4)
Use of decline in D-xylose absorption to predict infection following intensive chemotherapy. (1984) (4)
Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710 (2007) (4)
Is there a best TKI for chronic phase CML? (2015) (3)
New agents for induction and postremission therapy of acute myeloid leukemia (2001) (3)
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial (2022) (3)
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614) (2018) (3)
Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients (2014) (3)
Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) Among Adults with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) Achieving Remission with Blinatumomab (2016) (3)
CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights. (2006) (3)
Prognosis and Therapy When Acute Risk" Acute Myeloid Leukemias Occur as a Therapy (2011) (3)
Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors (2019) (3)
Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720). (2006) (3)
Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB). (2007) (3)
Gene Expression Patterns of Normal Human Skin, Actinic Keratosis, and Squamous Cell Carcinoma (2017) (3)
What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe? (2014) (3)
Geriatric Assessment (GA) May Identify Vulnerable Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients (2009) (3)
Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies (2013) (3)
Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable (2016) (3)
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy (2018) (3)
The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up (2011) (3)
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial. (2022) (3)
Relapse of Hodgkin's Disease After 14 Years of Complete Remission. (1990) (3)
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT (2022) (3)
Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP). (2007) (3)
Patients' perspectives on the definition of cure in chronic myeloid leukemia. (2019) (3)
Cardiac tamponade in a patient with chronic lymphocytic leukemia (2007) (3)
Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study (2010) (3)
Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial. (2021) (3)
Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study. (2015) (3)
Circulating immune complexes correlate with remission duration in acute myeloid leukemia. (1991) (3)
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101 (2022) (3)
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia (2019) (3)
Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication (2019) (3)
Phase II trial of decitabine in myelofibrosis with myeloid metaplasia (2007) (3)
Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study (2005) (3)
Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2021) (3)
Chronic lymphocytic leukemia masquerading as uveitis. (2007) (3)
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies. (2011) (3)
Myeloid Leukemia After Cytotoxic Therapy and Other Hematotoxins. (1998) (3)
Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation (2013) (3)
ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable9 Genetic Category (2011) (3)
Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB). (2005) (2)
Processing of bone marrow for transplantation: development of a mononuclear cell enrichment protocol. (1994) (2)
Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT). (2007) (2)
Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study (2017) (2)
FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia: An Evaluation of Efficacy of Target Inhibition and Relationship to Disease Progression (2015) (2)
A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). (2017) (2)
Two schedules of oral topotecan for Myelodysplastic Syndrome (MDS)-CALGB Study 19803 (2001) (2)
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study (2010) (2)
Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib (2014) (2)
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. (1990) (2)
Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL)-Preliminary results of CALGB 10001. (2006) (2)
Should therapy-related myeloid leukemia be treated like de novo acute myeloid leukemia? (2009) (2)
High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia. (1985) (2)
Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001 (2011) (2)
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia (2022) (2)
Acute myeloid leukemia: the challenge of unfavorable cytogenetics. (2012) (2)
An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups. (2007) (2)
The serial study of c-myc expression in bone marrow biopsy specimens during treatment for acute myelogenous leukaemia. (1993) (2)
Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas. (2004) (2)
Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. (2016) (2)
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells (1991) (2)
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia (2022) (2)
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity (2022) (2)
High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML). (2009) (2)
Perfecting the World: The Life and Times of Thomas Hodgkin (1798-1866) (review) (2015) (2)
Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients. (1993) (2)
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome (2020) (2)
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies (2004) (2)
FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study (2007) (2)
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (2)
Pre-treatment C-reactive Protein (CRP) is a Predictor for Allogeneic Hematopoietic Cell Transplantation Outcomes (2009) (2)
Decorin, a novel negative modulator of E-cadherin in inflammatory breast cancer (2020) (2)
Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia. (1992) (2)
A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia. (1988) (2)
Cholesterol and mevalonic acid are independent requirements for the in vitro proliferation of human bone marrow granulocyte progenitor cells: studies using ML-236B. (1983) (2)
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105. (2006) (2)
Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors (2008) (2)
Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710. (2006) (2)
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home (2009) (2)
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (2021) (2)
Economics influences therapy decisions in chronic myeloid leukaemia: should it? (2021) (2)
Abstract P3-01-10: Ndrg1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis (2020) (2)
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (2)
Therapy-Related Myeloid Neoplasms (t-MN) in 71 Patients Following Radiation Therapy (RT) Only, (2011) (2)
Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study. (2009) (2)
Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care. (2005) (2)
Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL) (2014) (2)
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). (2014) (2)
215 Update of open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS) (2011) (2)
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation (2018) (2)
Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation (2019) (2)
Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden. (2004) (1)
Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902 (2010) (1)
Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805. (2004) (1)
ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2022) (1)
Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. (2011) (1)
Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. (1991) (1)
chronic phase vs imatinib in patients with newly diagnosed chronic myeloid leukemia (2013) (1)
Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia. (2011) (1)
Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107. (2005) (1)
Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase (2021) (1)
Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance) (2014) (1)
Selection of optimal remission consolidation therapy for individual patients with acute myelogenous leukemia (2000) (1)
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia (2022) (1)
Efficacy and tolerability of a modified pediatric‐inspired intensive regimen for acute lymphoblastic leukemia in older adults (2021) (1)
Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16) (2011) (1)
Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. (2006) (1)
Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT). (2021) (1)
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. (2021) (1)
MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study (2007) (1)
Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies. (2006) (1)
Group B Study 9222 myeloid leukemia in adults under 60 years of age: Cancer and Leukemia cytarabine alone as postremission intensification therapy for acute Sequential multiagent chemotherapy is not superior to high-dose (2013) (1)
myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study cytogenetically normal patients younger than 60 years with acute markers, poor outcome, and a distinct gene-expression signature in High BAALC expression associates with other molecular prognostic (2013) (1)
The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago (2014) (1)
Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures, (2011) (1)
Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL) (2012) (1)
Therapy-related myeloid leukemia. A model for leukemogenesis (2009) (1)
Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML) (2015) (1)
A survey of current practices in the management of chronic myeloid leukemia (CML). (2011) (1)
Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine. (2006) (1)
Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU (1988) (1)
Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex (2016) (1)
Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I–II Study (2008) (1)
Therapy-related myeloid leukemia: stochastic or idiosyncratic? (2004) (1)
Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial) (2022) (1)
Results of Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B (2001) (1)
Errors in management of head and neck tumors (1968) (1)
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) (2018) (1)
DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML (2013) (1)
ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML) (2018) (1)
The DNA synthetic response of normal and abnormal human lymphocytes to mevalonic acid: the role of granulocytes as a helper population. (1984) (1)
97 CHARACTERISTICS OF ROMIPLOSTIM-TREATED MDS PATIENTS WITH HEMATOLOGIC IMPROVEMENT IN PLATELETS (HI-P) (2015) (1)
Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461. (2004) (1)
accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase (2008) (1)
Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance) (2013) (1)
Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis (2022) (1)
Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. (2009) (1)
Abstract 2717: Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study (2010) (1)
Heterogeneity of 06-Alkylguanine-DNA Alkyltransferase Activity in Peripheral Blood Lymphocytes : Relationship between This Activity in Lymphocytes and in Lymphoblastoid Lines from Normal Controls and from Patients with Hodgkin ' s Disease or Non-Hodgkin ' s Lymphoma 1 (2006) (1)
Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen. (2010) (1)
WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia (2016) (1)
Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B. (1983) (1)
A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes (2011) (1)
Blockade of Mir-150 Maturation by MLL-Fusion/MYC/Lin-28 Is Required for MLL-Associated Leukemia (2012) (1)
High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance) (2021) (1)
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia (2022) (1)
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. (2022) (1)
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study (2018) (1)
Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey (2018) (1)
Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd. (2010) (1)
Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy. (2006) (1)
Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies (2011) (1)
NILOTINIB SHOWS SUSTAINED BENEFIT COMPARED WITH IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 4-YEAR FOLLOW-UP (F/U) (2013) (1)
Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia (2016) (1)
Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)–An International Study (2011) (1)
B 8461 older with acute myeloid leukemia: results from cancer and leukemia group complete remission and long-term outcome in patients 60 years of age or Pretreatment cytogenetics add to other prognostic factors predicting (2011) (1)
Abstract PD6-06: Understanding the complexity of macrophage and mesenchymal stem cell interactions to improve treatment outcome for IBC patients (2018) (0)
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202. (2020) (0)
Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance? (2022) (0)
Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia (2017) (0)
Abstract 1600: Simvastatin targets breast cancer stem-like cells by inhibiting intracellular signaling pathways leading to radiosensitization of inflammatory breast cancer cells. (2013) (0)
Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403. (2020) (0)
lymphoma: Cancer and Leukemia Group B study 19801 refractory T-lineage acute lymphoblastic leukemia or lymphoblastic Nelarabine induces complete remissions in adults with relapsed or (2013) (0)
Dental management of cancer patients receiving chemotherapy. (1986) (0)
Identification of TET1⊣miR-22⊣CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia (2014) (0)
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. (2017) (0)
Characterization of Non-Adherent Cells from IPC-366, A Canine Inflammatory Mammary Cancer Cell Line (2017) (0)
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention (2022) (0)
Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710. (2010) (0)
Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B (2001) (0)
complete responses to high-dose cytarabine Short remission durations in therapy-related leukemia despite cytogenetic (2011) (0)
Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364 Value of Immunophenotype in Intensively Treated Adult Acute (2011) (0)
MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2011) (0)
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia (2004) (0)
Therapy-related myeloid neoplasms (t-MN) in 84 patients (pts) following radiation therapy (RT) only. (2016) (0)
Abstract 2039: Exploring the longitudinal transcriptomic landscape of tyrosine kinase inhibitor treatment response in chronic myeloid leukemia patients (2016) (0)
Allo-HSCT in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Blinatumomab vs Standard-of-Care Chemotherapy From a Randomized Phase 3 Study (2018) (0)
Randomized Control led Tria l o f Azac i t id ine in Pat ients With the Myelodysplas t ic Syndrome : A Study of the Cancer and Leukemia Group B (2017) (0)
myelogenous leukemia (letter) Interleukin-1 beta expression and treatment outcome in acute (2011) (0)
Treatment of Acute Lymphoblastic Leukemia in Middle-Age and Older Adults (2011) (0)
Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts). (2009) (0)
Leukaemia and myeloma LEUKAEMIA AND MYELOMA | 424OI The efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients with acute myeloid leukemia in first relapse (2005) (0)
t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study. (2004) (0)
P2-09-05: Molecular Imaging of Hedgehog Induced Epithelial-Stromal Interactions. (2011) (0)
A prospective feasibility study of clofarabine (CLO) cytoreduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS. (2010) (0)
17 IDENTIFYING DISTINCT DIFFERENTIATION/LINEAGE-SPECIFIC DRUG-SENSITIVE CHROMATIN STRUCTURE AND THE UNDERLYING NOVEL MUTATIONS IN MDS AND LEUKEMIAS (2015) (0)
Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors. (2016) (0)
FLT3 Inhibitor Maintenance after Allogeneic Stem Cell Transplantation in FLT3-Mutated Acute Myeloid Leukemia (AML) Patients (2023) (0)
Abstract 3051: The miR-200 family as a potential therapeutic target in inflammatory breast cancer. (2013) (0)
An evaluation of recipient-donor compatibility using class II allelic typing and cellular responsiveness (1994) (0)
Adult ALL: where are we and where are we going? (2004) (0)
P-180 Final report of an open-label extension (OLE) study of romiplostim in MDS with a focus on patients with prolonged treatment (2013) (0)
myelogenous leukemia Acquired FANCA dysfunction and cytogenetic instability in adult acute (2013) (0)
Feasibility of early withdrawal of immunosuppression (WOI) followed by dose escalation of prophylactic donor lymphocyte infusion (pDLI) after T-cell depleted (TCD) matched donor allogeneic hematopoietic cell transplantation (HCT). (2016) (0)
Abstract P6-16-01: The microRNA miR-141 is a key regulator of brain metastasis from breast cancer (2015) (0)
Leukemias: Association With Prior Therapy Translocations With Novel Partner Chromosomes in Myeloid (2011) (0)
ID: 26: EXPLORING THE LONGITUDINAL TRANSCRIPTOMIC LANDSCAPE OF TYROSINE KINASE INHIBITOR TREATMENT RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS (2016) (0)
Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML). (2004) (0)
Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer (2021) (0)
134 Molecular mapping of the DEL(5Q) in myelodysplastic syndromes (1997) (0)
Acute Myeloid Leukemia in Adults: Postremission Therapy (2009) (0)
Acute Leukemia (2021) (0)
Control of abdominal wall digestion after ileostomy breakdown — A complication of obesity (1969) (0)
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. (2023) (0)
myeloid leukemia in chronic phase treated with frontline nilotinib or Early molecular response predicts outcomes in patients with chronic (2014) (0)
Treatment-inﬂuenced associations of PML-RAR (cid:1) mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia (2012) (0)
Abstract 2397: Intracellular cholesterol regulates the DNA damage response in inflammatory breast cancer (2018) (0)
Abstract 3087: MicroRNA 141: A novel regulator of brain metastasis from breast cancer (2015) (0)
Epigenetic Modifying Drugs Inhibit MDS/AML Cell Growth through Selective Disruption of the Interactions Between Lineage-Determining Transcription Factors and DNA/Histone Modifiers (2015) (0)
WE‐EF‐BRA‐10: Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastasis in a Mouse Model of Metastatic Breast Cancerr (2015) (0)
Single center experience treating adults with FLT3-mutated acute myeloid leukemia (AML). (2012) (0)
Abstract P3-01-06: Decorin-mediated suppression of tumorigenesis and skin invasion in inflammatory breast cancer via inhibition of the E-cadherin/EGFR axis (2020) (0)
Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance) (2021) (0)
Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT) (2020) (0)
Results of Phase I/II VMAT-TMI Dose Escalation Study Of Patients Undergoing Second Allogeneic Stem Cell Transplantation (2020) (0)
Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study. (2007) (0)
lymphadenopathy Nonrandom chromosome abnormalities in angioimmunoblastic (2013) (0)
Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia (2003) (0)
Eltrombopag Is a Safe and Effective Agent to Treat Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) (2023) (0)
223: C-reactive protein (CRP) may predict transplant-related mortality after allogeneic hematopoietic cell transplant (HCT) (2007) (0)
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia (2018) (0)
Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes (2021) (0)
Management of Therapy‐Related Myeloid Neoplasms (2014) (0)
Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience. (2009) (0)
Microenviroment-mediated Induction of Protein Kinase C – zeta in Breast Inflammatory Carcinoma Cells as a Possible Mediator of Radioresistance. (2019) (0)
Caution in using second generation TKI, especially for first line therapy of CML. (2022) (0)
Acute Myeloid Leukemia in Adults: Remission Induction Therapy (2009) (0)
Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) (2018) (0)
Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study. (2012) (0)
Abstract P4-03-14: Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer (2017) (0)
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication (2021) (0)
Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia (2014) (0)
The University of Chicago experience with a reduced intensity allogeneic peripheral blood stem cell transplant preparative regimen using fludarabine, cyclophosphamide, and antithymocyte globulin (ATG) in pts with a hematologic malignancy. (2004) (0)
Listen to Thy Patient: Poor Quality of Life (QoL) Reported by Older Adults Prior to Allogeneic Stem Cell Transplantation (allo-HCT) Is Independently Associated with Worse Transplant Outcomes (2012) (0)
Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen. (2005) (0)
MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations. (2007) (0)
P1-04-03: The Effect of Survivin Downregulation on Radiosensitization of Breast Cancer Cell Lines Grown under Adherent and Stem Cell Promoting Culture Conditions. (2011) (0)
Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis (2015) (0)
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. (2023) (0)
Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study. (2004) (0)
White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance) (2021) (0)
Hematology/Oncology Clinics of North - America: Preface (2000) (0)
Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA) (2014) (0)
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. (2012) (0)
A Genome-Wide Analysis to Identify Novel Susceptibility Loci for Therapy-Related Acute Myeloid Leukemia (2008) (0)
Constipated myeloma Therapy-related myeloid leukemia: stochastic or idiosyncratic? (2004) (0)
252Valacyclovir compared to acyclovir for cytomegalovirus prophylaxis in allogeneic stem cell transplants recipients (2003) (0)
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study (2022) (0)
Abstract P6-15-04: Modeling limited breastfeeding and diet on IBC like tumor progression (2020) (0)
Methyl transferase activity in secondary leukemia. (1990) (0)
CMA-676: Mechanism of Action and Clinical Results (2003) (0)
Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation. (2005) (0)
Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation (2014) (0)
and whites with acute myeloid leukemia Differences in prognostic factors and outcomes in African Americans (2011) (0)
Treatment of Therapy-Related Myeloid Neoplasms with High-Dose Cytarabine/Mitoxantrone Followed by Hematopoietic Cell Transplantation (HCT). (2009) (0)
Group B Study leukemia patients with normal cytogenetics: a Cancer and Leukemia BAALC expression predicts clinical outcome of de novo acute myeloid (2013) (0)
he Role of Cytotoxic Therapy with ematopoietic Stem Cell Transplantation in the herapy of Acute Lymphoblastic Leukemia in hildren: An Evidence-Based Review (2005) (0)
Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23 (2005) (0)
A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable. (2005) (0)
Phase II Trial of Oral Aminopterin forAdults and Children with RefractoryAcute Leukemia (2005) (0)
Abstract P5-03-10: HIF-1alpha knockout radiosensitizes select Inflammatory Breast Cancer cells through reduction of stem-like cancer cells (2012) (0)
Acute Myeloid Leukemia : The Challenge of Unfavorable Cytogenetics August (2017) (0)
Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data (2021) (0)
Abstract A55: A novel mediator of brain metastasis from breast cancer (2016) (0)
Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from a randomized phase III study. (2017) (0)
Abstract P5-03-05: Histone deacetylase (HDAC)-inhibitor mediated reprogramming drives cancer cells to the pentose phosphate metabolic pathway (2012) (0)
Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers (2022) (0)
RNA/HnRNPK and BRD4/BET Mediate 5-Azacytidine (5-AZA) Action and Resistance in MDS/AML (2017) (0)
Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality (2016) (0)
PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY (2019) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (0)
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases. (2004) (0)
Abstract 4470: RNA m5C methyltransferases and hnRNPK mediate disease-associated chromatin structure and drug resistance in leukemia (2017) (0)
leukemia Endpoints to establish the efficacy of new agents in the treatment of acute (2013) (0)
MYELOID NEOPLASIA Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (2013) (0)
Faculty Opinions recommendation of Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. (2008) (0)
Efficacy a nd S afety o f G emtuzumab O zogamicin i n P atients With C D33-Positive A cute M yeloid L eukemia i n F irst Relapse (2001) (0)
Transcription factors activated by chromosomal translocations in human cancer (1993) (0)
OP17 Arsenic trioxid improves survival in first line APL consolidation treatment: the NCI/CALGB study results (2007) (0)
Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only (2020) (0)
Depend on Increased Metabolism Activate Growth and Survival Pathways Human Acute Myeloid Leukemia That in CBL Novel Oncogenic Mutations of Signal Transduction (2010) (0)
leukemia postconsolidation therapy in younger patients with acute myeloid A phase 3 study of gemtuzumab ozogamicin during induction and (2013) (0)
Can We Do Better In Management Of Neutropenic Fever In Hematological Patients (2010) (0)
Abstract P1-03-01: Lipoproteins regulate the effects of macrophages and mesenchymal stem cells on radiation response of inflammatory breast cancer cells (2016) (0)
chronic myeloid leukemia: 2013 European LeukemiaNet recommendations for the management of (2013) (0)
Abstract B69: Mesenchymal stem cells promote tumor-skin involvement in inflammatory breast cancer models (2013) (0)
Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. (2008) (0)
MicroRNAs and copy number changes: New levels of gene regulation in acute myeloid leukemia (2010) (0)
Acute Leukemia in Adults (2003) (0)
Heterogeneity in the O6 Alkylguanine DNA Alkyltransferase (AGT) Activity of Human Peripheral Blood Lymphocytes (PBL’s) (1989) (0)
Leukemia Group B Study 9511 improved outcomes in adult acute lymphoblastic leukemia: Cancer and Effective asparagine depletion with pegylated asparaginase results in (2013) (0)
Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) (2014) (0)
Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia (2021) (0)
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (0)
Outcomes in Patients With FLT3-Mutated R/R AML Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib Versus Salvage Chemotherapy. (2022) (0)
Clinical and molecular response of AML harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors (2022) (0)
Abstract P6-06-08: Transcriptome analysis of patient derived xenograft mouse models of inflammatory breast cancer to gain insights into the contribution of tumor microenvironment (2020) (0)
Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results (2020) (0)
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS (2019) (0)
Leukemia Group B study myeloid leukemia and MLL partial tandem duplication: a Cancer and Long-term disease-free survivors with cytogenetically normal acute (2013) (0)
PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY (2019) (0)
Comparison of four categorized risk scoring systems for analyzing outcome in advanced MDS (1994) (0)
Genomic Rearrangements Associated with -5/del(5q) and -7/del(7q) in Myeloid Leukemias. (2007) (0)
ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760) (2005) (0)
Cancer and Leukemia Group B Studies in Acute Lymphoblastic Leukemia (1994) (0)
P1-04-01: The Mechanism of Anti-Breast Cancer TICs Effect of Pyrvinium Pamoate Is through WNT/beta-Catenin Signaling. (2011) (0)
Supplementary Material for: Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia (2016) (0)
Detection of combinations of cytogenetic abnormalities in chronic lymphocytic leukemia (CLL) by fluorescent in situ hybridization (FISH) probes. (2010) (0)
Therapy-Related Acute Promyelocytic Leukemia (2018) (0)
High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults with Acute Myeloid Leukemia (2021) (0)
CCTG on the world stage at ASCO 2017 (2020) (0)
I-020 The syndrome of therapy-related myeloid neoplasms (2013) (0)
New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT). (2006) (0)
MPN-288: Molecular Characteristics of IDH2-Mutated, Philadelphia Chromosome-Negative, Advanced-Phase Myeloproliferative Neoplasms Treated with Enasidenib (2020) (0)
Acute Leukemia (2021) (0)
Is Family History of Breast Cancer Associated with Therapy-Related Myelodysplastic Syndrome and Therapy-Related Leukemia? . (2004) (0)
Abstract 1624: Silencing of ERK2 reverses EMT and suppresses the CSC phenotype, inhibiting lung metastasis in triple-negative breast cancer (2016) (0)
The Response of Human Cells to In Vivo Methylation Damage (1989) (0)
Low 06-Alkylguanine DNA AIkyItransf erase Activity in the Peripheral Blood Lymphocytes of Patients with Therapy-related Acute Nonlymphocytic Leukemia 1 (2006) (0)
Obesity in Children with Acute Promyelocytic Leukemia: What is its Incidence and Prognostic Significance? (2021) (0)
A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance) (2014) (0)
Nonrandom Chromosome Abnormalities in Angioimmunoblastic (1982) (0)
acute leukemia End points to establish the efficacy of new agents in the treatment of (2013) (0)
Abstract CT023: A phase I study of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with induction and consolidation chemotherapy for adult patients (pts) with newly diagnosed acute lymphoblastic leukemia (ALL) (2018) (0)
Abstract P5-07-04: Characterization of a new canine inflammatory mammary cancer (IMC) cell line (IPC-366) (2015) (0)
Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. (2004) (0)
Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML) (2015) (0)
CML-109: Exploratory Biomarker Analysis from ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) from Poor Response in Chronic Myeloid Leukemia (CML) (2020) (0)
patients with de novo acute myeloid leukemia : results from Cancer and success , cumulative incidence of relapse , and overall survival in adult Pretreatment cytogenetic abnormalities are predictive of induction (2002) (0)
167. The proliferative rates of acute myelogenous leukemia cells can be accelerated or slowed in vivo in patients (1992) (0)
Author reply to Fujimi et al (2012) (0)
Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720). (2007) (0)
Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia (2011) (0)
Prior invasive fungal infection does not preclude successful allogeneic transplantation (2006) (0)
TARGETING RNA EPIGENETICS TO PREDICT AND OVERCOME DRUG RESISTANCE IN MDS AND AML (2023) (0)
study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with (2013) (0)
Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (0)
Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding FactorAcuteMyeloid Leukemia (2008) (0)
PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO-MUTATIONS OR A HIGH FLT3-ITD ALLELIC RATIO (2019) (0)
Acute Leukemia (2021) (0)
Abstract 2309: Down-regulation of miR-181b contributes to the poor prognosis of adverse cytogenetically abnormal acute myeloid leukemia by targeting PBX3 (2012) (0)
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase (2011) (0)
Inherited cancer predisposing mutations in patients with therapy‐related myeloid neoplasms (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard A. Larson?

Richard A. Larson is affiliated with the following schools:

University of California, Berkeley
MD Anderson Cancer Center
Ohio State University
Dartmouth College
University of Chicago
Case Western Reserve University
University of Bologna
Karolinska Institute
Duke University
University of Münster

Richard A. Larson's Academic­Influence.com Rankings

Why Is Richard A. Larson Influential?

Richard A. Larson's Published Works

Published Works

What Schools Are Affiliated With Richard A. Larson?

Richard A. Larson's AcademicInfluence.com Rankings